You are here: Industry Insights > ASLAN Pharmaceuticals

News List

ASLAN Pharmaceuticals acquires rights to atopic dermatitis asset pharmaceutical-technology
June 05, 2019
ASLAN Pharmaceuticals has amended its licensing agreement with CSL to obtain complete worldwide rights to develop, manufacture and commercialise fully human monoclonal antibody (mAb) ASLAN004 across all indications.
Aslan Pharmaceuticals amends license agreement with CSL biospectrumasia
June 03, 2019
Amending their previous agreement, CSL grants ASLAN full global rights to develop, manufacture and commercialise ASLAN004
ASLAN signs news commercialisation agreement with BioGenetics biospectrumasia
March 11, 2019
ASLAN will grant BioGenetics exclusive rights to commercialise ASLAN003 in South Korea in exchange for an upfront payment of US$1 million and up to US$8 million in sales and development milestones.
ASLAN prices IPO of its American depository shares biospectrumasia
May 08, 2018
Leerink Partners and Piper Jaffray & Co. are acting as joint book-running managers for this offering.